INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 7, July 2026 | ISSN: 2456-4184 | IJNRD.ORG

Pharmacological Approach To Combatting Anti - Biotic Resistance

Ms. Tejasvi B Salve[1], Mr. Mayur B Pachunde[2], Dr. Gajanan S Sanap[3].
Late Bhagirathi Yashwantrao Pathrikar College of D pharmacy (D & B), Pathri Phulambri Chh.Sambhajinagar 431111

Abstract

Antibiotic resistance poses a significant threat to global health, with multi-drug resistant pathogens leading to increased morbidity and mortality. This review discusses the mechanisms employed by bacteria to resist antibiotics and explores innovative pharmacological approaches to mitigate this challenge. Key strategies include the development of novel antibiotics, repurposing existing drugs, combination therapies, anti-virulence strategies, and emerging technologies such as CRISPR-Cas systems and phage therapy. By examining these approaches, this review aims to provide a comprehensive understanding of current and future strategies to combat antibiotic resistance.

Keyword: Antibiotics, Future, Policies, Resistance, prodrug, Drug resistance – cancer, Multidrug resistance - Drug efflux,

1. Introduction

One of the most effective types of chemotherapy in medical history is most likely antibiotics. They have prevented the death of millions of people and brought an end to most of the infectious diseases that have afflicted humanity for centuries. When antibiotics were first used in clinical settings in the 1940s, they were so effective at eliminating harmful germs that many people thought infectious diseases would soon be eradicated from all human populations. But in recent decades, antibiotic-resistant pathogens—particularly multi-drug-resistant bacteria—have emerged and spread quickly, exposing our ignorance of the ecological and evolutionary processes occurring in microbial eco-systems. Microbial communities are known to have a great deal of metabolic variety, which they can use to develop defence mechanisms that enable them to withstand the selective pressures of both their natural environment and human interventions like antibiotics.

The microbiota and other community members exhibit adaptive phenotypic and genotypic responses as a result of this signaling caused by non-clinical doses of antibiotics in the environment. At least with regard to the more recent antibiotics that are now being used in clinical settings, an understanding of the intricate relationship between the ecology and evolution of antibiotics and antibiotic resistance may aid in both understanding and controlling the processes that lead to the emergence and spread of antibiotic resistance. Overview One of the most effective types of chemotherapy in medical history is most likely antibiotics. [1]

*** Overview of Antibiotic Resistance**

2. Definition

Pathogenic microorganisms that exhibit antibiotic resistance can be classified either clinically or microbiologically. When a genetically determined resistance mechanism (acquired or mutated) is present, microbiological resistance is present, classifying the infection as resistant or susceptible in a phenotypic laboratory test by applying a predetermined cut-off. A degree of antibiotic resistance is called clinical resistance. Behavior associated with a greater probability of therapeutic failure; that is, administering a medication to a pathogen that When tested susceptible, it yields greater results than is obtained using a medication that the virus has proven resistant to. In order to identify clinical resistance, the test cut-offs can differ with elements of the clinical environment, including the infection site or the dosage of the medication.

Antibiotic resistance may be acquired or intrinsic, meaning it is present in all isolates of that species. All Gram-positive organisms' resistance to colistin, Enterobacteriaceae's resistance to glycopeptides and linezolid, and an example of intrinsic antibiotic resistance are a variety of drugs to Pseudomonas aeruginosa. [1]

3. Scope Of Antibiotic Resistance

Antibiotics for ulcerative colitis to induce and sustain remission . Antibiotic prevention treatment for COPD patients

1. COPD:- What is it? People who currently smoke or have smoked in the past are primarily affected by COPD, a common chronic respiratory disease. It might turn into the third most common cause of death globally by 2020. Shortness of breath and coughing get worse with time for those with COPD. Sputum (phlegm) due to irreversible harm to their lungs and airways.

2. Why did we conduct this review? We investigated if 'prophylactic' antibiotics could lessen flare-ups and improve quality of life. Studies that were taken into consideration employed either continuous prophylactic antibiotics (every day), or antibiotics .They were used sporadically (three times per week) or pulsed (for example, five days every eight weeks).

The global problem of antibiotic resistance, also known as antimicrobial resistance (AMR), has an impact on the environment, the food chain, and the health of humans and animals.

1. Health :- Treatments for common illnesses and life-saving operations like organ transplants and treatment for cancer are at risk due to antimicrobial resistance. Additionally, it makes more costly and intensive treatment necessary.
2. Food Chain:- AMR poses a hazard to food security and can lower agricultural production.
3. Environment : - Resistance characteristics can be introduced into the environment using AMR. Among the primary environmental hotspots are wastewater treatment facilities, animal dung, aquaculture operations, and hospital effluents.
4. Global impact:- AMR can impact health systems and national economies across all income levels. It can also undo the benefits of effective antibiotics, which include reducing disability, health-care expenses, and prolonging life.
5. Vulnerable groups of people :- AMR disproportionately affects populations that are already at risk, including the elderly, children, and those with long-term illnesses.
6. World wide death rate :- By 2050, if AMR is not tackled, it may overtake all other causes of death globally. AMR-related direct mortality were predicted to reach approximately 1.2 million in 2019.

4. Impact on Global Health

Morbidity :- Among the worldwide health problems that raise mortality rates are

1.Non-communicable illnesses :-
Diabetes, cancer, heart disease, and chronic respiratory conditions are a few of these Alcohol and tobacco use, obesity, poor eating habits, and a lack of physical activity are risk factors.

2.Mother Death :-
With access to high-quality care during pregnancy, childbirth, and after delivery, the majority of maternal deaths can be avoided.

3.Infant Death :-
can be avoided with access to a healthy diet, clean water, hygienic conditions, and vaccinations.

Morbidity is a term for illness, and prevalence is a measure of how prevalent a disease is in a population. Some global health issues including :-

1.Illnesses that do not spread (ncds) :-These consist of long-term respiratory conditions, diabetes, cancer, and heart disease. Globally, ncds account for almost 70% of all fatalities. Air pollution, poor diets, alcohol and cigarette use, and physical inactivity are risk factors for non -communicable diseases (ncds).

2.COVID-19 :-
COVID-19 ranked as the second most common cause of death worldwide in 2021. The WHO concluded COVID-19 as a public health emergency in May 2023, but emphasized that the illness remains a hazard to the entire world.

3.Mental health:- Mental health issues can be exacerbated by risk factors for ncds. Half of all mental illnesses begin by age 14, but most cases go untreated. Suicide is the third leading cause of death among 15-19 year-olds.

2 . Mortality :-
Heart and lung conditions, as well as COVID-19, are the main causes of death worldwide.

1.Ischemic Heart Disease :- The primary cause of death worldwide, accounting for 13% of all fatalities
2.COVID-19 :The second most common cause of death worldwide in 2021, accounting for 8.7 million fatalities.
3.Lower Respitatory Infection :- Reduce the incidence of respiratory illnesses Other than COVID-19, the world's most deadly communicable disease and the sixth greatest cause of death in 2021
4.Alzheimers Disease :- Alzheimer's disease as well as additional dementia types one of the top ten causes of death globally and the third most common in the Americas AND Europe.
5. Diabetes :- One of the top 10 causes of death worldwide, diabetes saw a 70% increase in deaths from 2000 to 2019.

3.Economic burden :- Global health problems can have a large financial cost, particularly in low- and middle-income nations:

1.Infectious Illnesses :-
According to a 2020 study, the eight main infectious diseases caused $8 trillion in worldwide economic damage in 2017. From 2015 to 2017, the Zika pandemic is projected to have cost Latin America and the Caribbean between $7 and 18 billion.

2. AIDS, TB, and malaria :-
Patients with these disorders and their families may incur significant costs, particularly in regions with limited resources.

3. COPD stands for chronic obstructive pulmonary disease:-
The economic expense of COPD is largest in high-income nations, whereas low-income and middle-income countries incur the biggest health impact.

4.COVID-19 :-
Health care professionals suffered a crippling financial burden from COVID-19 infections, with expenses differing by nation.

The following are other elements that may increase the financial cost of health problems: -
1. Weaknesses in the health system, including inadequate coverage, subpar care, and user fees growing costs for food
2. Degradation of the environment and global warming
3. New infections
4. Non-communicable illnesses stress
5. Mishaps and psychological About antibiotic-resistant bacteria

Some bacterial strains have developed resistance to popular antimicrobial chemotherapies as a result of the over prescription of antibiotics over the past few decades.

Methicillin-resistant Staphylococcus (MRSA), for instance, is a form of bacteria that can cause a serious infection that is resistant to numerous medications. In order to properly treat these forms of bacteria that are resistant to antibiotics, medical experts are trying to create new kinds of antimicrobial chemotherapy. [2]

5. Causes of antibiotics resistant :-

Over time, bacteria develop a natural resistance to treatments. However, a few things can expedite the procedure, such as :-

1. Overuse of antibiotics:- Overuse In 1945, Sir Alexander Fleming warned against antibiotic misuse, stating that the "public The demand for the medication will lead to a new era of abuses."7,14 Antibiotic usage obviously contributes to the evolution of resistance.5,9 Epidemiological investigations have shown There is a direct association between antibiotic use and The establishment and spread of resistant bacterium strains.10 Genes in bacteria may be inherited from relatives or obtained from nonrelatives on movable genetic elements such as plasmids. Horizontal gene transfer (HGT) can spread antibiotic resistance across bacterial species. Resistance can also arise spontaneously through mutation. Antibiotics eliminate drug-sensitive rivals. As a result, resistant bacteria survive and proliferate of Natural Selection. Despite warnings about usage Antibiotics are overprescribed worldwide.

2. Inappropriate Prescriptions :-Incorrectly prescribed antibiotics also contribute to the spread of resistant micro-organisms. Five studies indicate that therapy The indication, agent selection, and duration of antibiotic therapy are In 30 to 50 percent of cases, the answer is inaccurate.5,18 According to one study conducted in the United States
Only 7.6% of the 17,435 patients had a pathogen identified. I was hospitalized for community-acquired pneumonia (CAP).In comparison, researchers from the Karolinska Institute in In 89% of cases, Sweden identified the probable pathogen. Patients with CAP were diagnosed using molecular diagnostic techniques (polymerase chain reaction [PCR] and semiquantitative PCR). Furthermore, 30-60% of the antibiotics administered in Intensive care units (icus) were discovered to be unneeded unsuitable or substandard. Incorrect antibiotic prescriptions may not provide therapeutic benefit and can lead to problems. Antibiotic resistance is developed through genetic modifications, including gene expression changes, HGT, and mutagenesis. Changes: Antibiotic-induced gene expression can enhance pathogenicity. Increased mutagenesis and HGT promote antibiotic Resistance and Spread the bacteria . Low antibiotic doses can lead to strain diversification in organisms Pseudomonas aeruginosa.

3. Extensive agricultural use:-Antibiotics are commonly utilized to enhance livestock growth in both developed and developing countries. Approximately 80% of antibiotics sold in the United States are used to treat animals. The primary objectives are to stimulate growth and prevent infection. Antimicrobial treatments for animals are thought to improve the general health of the animals, resulting in higher yields and High-quality stuff. Antibiotics used in livestock are consumed by humans. When they eat food. The transmission of resistant germs. More than 35 years ago, it was discovered that farm animals caused harm to humans. Previously, large rates of antibiotic resistance were discovered in The gut flora of farm animals and farmers.

4. Availability of Few New Antibiotics :-The pharmaceutical industry's successful approach of developing new antibiotics to tackle resistant germs has paused. Economic and regulatory challenges Fourteen of the 18 major pharmaceutical companies, 15 abandoned the antibiotic field. Antibiotic development is no longer an economically viable investment for the pharmaceutical business. Antibiotics are used for very brief periods of time Antibiotics are typically curative, although they are not as profitable as pharmaceuticals. That address chronic illnesses, such as diabetes, mental Disorders, such as asthma or gastric reflux. The cost- Benefit analysis by the Office of Health Economics in London. Calculated the net present value (NPV) of a new antibiotic is only about $50 million, compared to almost $1 billion for a medication used to treat neuromuscular illness .

6. Mechanism of Resistance :-

1. Genetic Mutation :- Bacteria use active efflux, an energy-dependent process, to reduce antimicrobial concentrations within their cells. Efflux pumps are naturally found in both vulnerable and resistant microorganisms. Gram-negative bacteria Efflux pumps are frequently chromosomally encoded, and most strains have genetic determinants for numerous pumps, establishing an inherent resistance to a multiplicity of antimicrobials. Efflux mechanisms can provide resistance against a certain Antimicrobial agent, class, or a number of antimicrobials that result in multidrug there's opposition. Efflux-mediated resistance is typically linked to mutations in either the efflux system's regulatory or effector genes. A mutation is a change in an organism's DNA sequence. Errors in DNA replication that occur during cell division, exposure to mutagens, or viral infections can all lead to mutations. Somatic mutations, which happen in body cells, cannot be passed on to progeny, whereas germline mutations, which happen in eggs and sperm, can.

Although our cells are constantly undergoing mutations, only few of these have an impact on our health. This is not at all like the science fiction that we typically see in movies. A mutation in real life rarely has the favorable effect of making a person a superhero or giving them strange abilities like wings. There are several explanations for why mutations typically have little to no negative effects. Recently, bacteria have been found to have several resistance pathways against a single antibiotic class, raising concerns. Resistance to b-lactam antimicrobials can be caused by multiple factors, including those mentioned above. Described mechanisms. The most common mode of b-lactam resistance is Production of b-lactamase enzymes, which physically degrade the antibacterial.[3]



Fig no . 1Genetic Mutation

2. Horizontal Gene Transfer :-

Biofilms promote nucleic acid exchange and recycling due to the closeness and long retention period of cells within the EPS matrix . Through a variety of methods, bacteria's genetic composition is shaped by their constantly changing surroundings. Point mutations and recombination modify the bacterial genome and are the first steps toward genetic diversity. Genetic material is passed both vertically and through HGT. This technique is capable of transforming innocuous bacteria into significant human diseases. HGT can occur through direct cell-to-cell contact (conjugation), the uptake of extracellular naked DNA by competent cells (transformation), or bacteriophage-mediated DNA transfer (transduction).
A fourth process describes the transfer of genetic material through cell fusion by outer membrane vesicles (omvs).

The flow of genetic information across organisms is known as horizontal gene transfer (HGT), and it is this process that drives disease evolution by allowing antibiotic resistance genes to proliferate among bacteria (apart from those passed from parent to offspring).

1. Transformation: Environmental DNA is absorbed by bacteria

2. Conjugation: Genes are transferred straight from bacteria to another cell.

3. Transduction: The transfer of genes from one cell to another by bacteriophages (bacterial viruses)

After being transmitted, infections and genes continue to change, frequently leading to more resistant bacteria. Natural selection may cause all genes, including virulence determinants, to spread horizontally and multiply. These genes are not limited to those that cause drug resistance. Many resistance genes are rapidly spreading to and among human diseases, despite having originated long ago in natural settings free from human impact. Three well-known genetic pathways (Fig.1) are responsible for HGT.[4]



Fig No.2 Horizontal Gene Transfer

3. Efflux Pump :-

Overcoming efflux-mediated antimicrobial resistance. Given the importance of efflux mechanisms, especially multidrug efflux mechanisms of the RND Antimicrobial resistance in key human infections must be addressed.

Efflux-mediated antibacterial resistance efflux in designing and developing novel antimicrobials. And in utilizing existing agents. One approach is to Develop agents that are less affected by recognized efflux mechanisms. The early 20th century saw the discovery of penicillin and streptomycin, ushering in the antibiotic age in which previously thought to be fatal bacterial illnesses could be readily treated. The "golden age" of antibiotic discovery occurred in the middle of the 20th century, as about half of the drugs currently in use were found at that time.

Antibiotic-resistant bacteria have been selected as a result of the widespread use, abuse, and misuse of antibiotics, which has accelerated the evolution of germs. According to estimates from the USA's Centers for Disease Control and Prevention (CDC), over 30% of antibiotic prescriptions for outpatients are superfluous. The issue has also been made worse by the careless use of broad-spectrum antibiotics as growth promoters in animal agriculture.

It is reasonable to assume that avoiding these resistance factors may enhance the effectiveness of substrate antibiotics, given the role efflux plays in mediating antibiotic resistance.[5]



Fig no . 3 Efflux Pump

4. Enzymatic Degradation :-Antibiotic resistance can occur through three mechanisms: preventing the medicine from interacting with the target, removing the antibiotic from the cell, and modifying the molecule. This review focuses on the chemical strategies for antibiotic inactivation, including hydrolysis, group transfer, and redox processes. While hydrolysis is extremely essential clinically, particularly when used with h-lactam antibiotics, the group transfer techniques are the most diverse and include modifications by acyltransfer, phosphorylation, glycosylation, nucleotidylation, and ribosylation and thiol transfer. Enzymes that physically alter antibiotics have a unique feature: they actively diminish Researchers and clinicians face a particular problem due to the concentration of medications in the local environment. The technique most frequently employed to liberate particles trapped in hydrogels or droplets is enzymatic breakdown. The droplet can be broken down as it passes through the microfluidic channel by coating it with the enzymes. Enzymatic solutions can be utilized to release particles trapped by immune affinity binding captured particles, in addition to releasing particles in hydrogels and droplets (Wei et al., 2019). The type of particles, the enzyme employed, and the needs of the experiment will

all affect the particulars of enzymatic degradation for particle release in a microfluidic channel. Enzyme concentration, reaction time, and flow conditions are important variables to carefully evaluate since they may need to be adjusted for effective particle release while reducing unfavorable outcomes like non-specific degradation or enzyme denaturation. Enzymes catalyze polymer chain scission, which is the process of enzymatic breakdown. The majority of the enzymes responsible for the breakdown of biodegradable polymer materials are non- plasma specific enzymes like lipases, phosphatases, and amylases[6]



Fig no .3 Enzymatic Degradation

5. Target modification:-

Antibiotic target site alterations are a typical mechanism of resistance. Resistant clinical strains exist for all antibiotic classes and mechanisms of action. Antibiotics can cause spontaneous mutation and selection of bacterial genes, leading to target site alterations. Examples include: Mutations in RNA polymerase and DNA gyrase confer resistance to rifamycins and quinolones, respectively. In other In some circumstances, resistance acquisition may involve the transfer of resistance genes from other organisms via some sort of genetic. Exchange (conjugation, transduction, or transformation). Examples of these methods include the acquisition of the meca genes. One prevalent mechanism of resistance to antibiotics is alteration of the target sites. Regardless of the antibiotic's mode of action, clinical isolates exhibiting resistance can be found for every type of medication. Target site alterations are frequently the consequence of selection acting in the presence of the antibiotic and spontaneous mutation of a bacterial gene on a chromosome. DNA gyrase and RNA polymerase mutations, which cause resistance to quinolones and rifamycins, respectively. In other situations, the acquisition of resistance could entail the conjugation, transduction, or transformation of resistance genes from other organisms . These pathways include Staphylococcus aureus acquiring the meca genes that encode methicillin resistance and enterococci acquiring the different van genes that encode glycopeptide resistance. Owing to the essential biological roles of the target locations, organisms are unable to completely circumvent the effects of antimicrobial agents. It is plausible that the target may undergo mutational modifications that diminish its vulnerability to inhibition without compromising cellular functionality.[3]



Fig no :- 4 Target Modification

7.Pharmacological strategies to combat Anti biotic Resistance :-

Combining traditional and modern treatments, including bioenhancers. Despite advances in pharmacology and traditional chemistry for producing novel synthetic antibiotics, substantially changing current medicines or identifying appropriate enzyme targets against which inhibitors can be developed; existing global drug research programmes may not be able to provide new effective antibiotics. For the following decade increased acquired resistance to When traditional antibiotics are detected, it is sensible to try combination therapy with plant extracts that possess bioenhancing action to achieve bactericidal synergy. Use of this combo therapy against resistant Bacteria may lead to newer treatments for infectious diseases.

The following are some pharmacological approaches to counteract antibiotic resistance:

1.Antibiotic stewardship:- Cautionary use of antibiotics according to guidelines, diagnostic tests, and other information

2.Novel antibiotics:- Creating Novel Antibiotics

3.Controlled use:- Reducing the amount of antibiotics given to food animals

4.Education:- Spreading knowledge about antibiotics and bacterial illnesses among patients, kids, the general public, and medical professionals
Synthetic particles are used as enzyme inhibitors to prevent the catalytic activity of enzymes.

5.Medicinal plants and phytochemicals:- Using natural compounds found in plants to counteract antibiotic resistance .

8. Inhibition of Resistance Mechanism

Antibiotic resistance in pathogens poses an immediate threat to our medical system's ability to treat bacterial infectious diseases due to its onset, prevalence, and fast spread.

In contrast to traditional antibiotics, which work by directly attacking the elements or stages of bacterial growth, inhibitors of resistance enzymes are always inactive or have very limited direct antibacterial effect. On the other hand, by selectively binding to the active site or blocking the transcription and translation of resistance genes, these inhibitors may reduce the activity of resistance enzymes. One useful inhibitor of β-lactamase is clavulanic acid, a naturally occurring substance containing β-lactams.

1.Enzyme Inhibitors :-

In general, substrate analogs and transition state analogs are the two categories into which enzyme inhibitors fall. Both varieties of analogs work by essentially competing with the substrate to bind to the enzyme's active site, but they are unaffected by the enzyme itself. While transition state analogs contain certain structural traits specific to the transition state, substrate analogs imitate the structural features of the substrates. Depending on whether the chemicals bind to the enzyme precisely or if the modification process depends on the catalytic mechanism of the enzyme, the activities of such chemicals arise from the modification of active-site residues of enzymes and may or may not be specific.[7]

9. Drug Conjugates and Hybrid Antibiotics :- Combination of drugs and novel molecules to bypass resistance mechanism

Hybrid antibiotics are an emerging solution to combat resistance development. Unfortunately, combination therapy has some major downsides. The effect of a specific combination therapy In vitro does not necessarily result in a clear response in vivo due to to the varied pharmacokinetic characteristics of the medicines when combined . As a result, the formulation must be fine-tuned to guarantee that the in-vivo concentrations are the same as the tablet. Additionally, this method cannot Address the issue of those MDR strains demonstrating the developed resistance to both medication groups in combination. This needs the use of additional drug families. In combination. A modest number of strong antibacterial The implementation of this strategy is significantly limited by drug families. For that purpose. Hybrid medications, sometimes known as "multiple ligands" or "single molecule multiple targets," are the most advanced type of combination therapy. They are designed via molecular hybridization—a approach of rational drug design which permits the fusing of one or more bioactive chemicals or their pharmacophoric subunits into one molecule, which represents the preselected, desirable properties of original medications . Connected entities should, of course, continue to have affinity for their particular targets and offer a better therapeutic impact by amplification of multifaceted biological action .

A multi-pharmacophore mode is typically followed in the design of multi-targeted medicines. According to IUPAC, a pharmacophore is "an ensemble of steric and electronic features that is necessary to ensure optimal supramolecular interactions and to trigger (or block) its biological response" with a particular biological target. Based on the extent of pharmacophore overlap, the four different types of multi-pharmacophore models are as follows: conjugated pharmacophore (with non-cleavable or cleavable linker), fused pharmacophore, merged pharmacophore . [7]

10. Novel antibiotics

1. Glycopeptides and Lipopeptides :-Natural or semisynthetic highly glycosylated ripps, known as glycopeptide antibiotics, are frequently used to treat infections caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus

2. Treatment of Gram Positive Bacteria and MRSA :- About antibiotic-resistant bacteria :-

Gram-negative microbes, including MDRAB, pose a significant hazard to public health. Currently, combating them. Infections frequently demand employing a last resort. Agents, such as colistin, which frequently have Suboptimal activity when utilized as monotherapy is connected with serious Toxicities include nephrotoxicity.

Combination Treatment with various antimicrobial agents has proved effective in the treatment of MDRAB. However, data are confined to retrospectives. Studies with small sample sizes Promising novel combinations of colistin and Gram-positive active agents, such as glycopeptides Lipopeptide antibiotics were explored. Primarily in vitro and in vivo. Future Investigation to obtain understanding into the clinical The influence of various combinations is necessary to Determine the potential benefits associated with Using such combinations .Some bacterial strains have developed resistance to popular antimicrobial chemotherapies as a result of the over prescription of antibiotics over the past few decades. Methicillin-resistant Staphylococcus (MRSA), for instance, is a form of bacteria that can cause a serious infection that is resistant to numerous medications. In order to properly treat these forms of bacteria that are resistant to antibiotics, medical experts are trying to create new kinds of antimicrobial chemotherapy.

Many antibiotics, such as the following, can be used to treat methicillin-resistant Staphylococcus aureus (MRSA) and gram-positive bacteria: -

1. The first-line antibiotic for MRSA infections is vancomycin, a glycopeptide. It is used to treat diseases such as bacteremia, pneumonia, osteomyelitis, and soft-tissue infections and is effective against the majority of Gram-positive bacteria.

2. Fifth-generation cephalosporins, quinupristin/dalfopristin, tigecycline, linezolid, and daptomycin are antibiotics that can treat Gram-positive pathogens that are increasingly resistant.

3. An antibiotic called clindamycin is effective against both anaerobic and Gram-positive bacteria.

4. Ophthalmic quinolones: Both Gram-positive and Gram-negative bacteria can be successfully combatted with these antibiotics. [8]

11. Oxazolidinones

First created at E.I. du Pont de Nemours & Co. In the middle of the 1980s, oxazolidinones are a completely synthetic class of bacteriostatic drugs that have no congeners in natural product compounds. Pharmacia (now Pfizer Inc., New York, NY, USA) subsequently adopted them By interacting with the 50S subunit's A-site pocket in the peptidyl transferase center (PTC), oxazolidinones prevent the production of new proteins. This interaction stops trna from binding at the A site and modifies the initiator-trna's binding and/or placement. Consequently, the translation sequence is prevented A novel class of antibiotics is called oxazolidinones. These synthetic medications exhibit efficacy against a wide range of Gram-positive bacteria, include anaerobes, vancomycin-resistant enterococci, methicillin- and vancomycin-resistant staphylococci, and penicillin-resistant pneumococci. By attaching to the P site of the ribosomal 50S subunit, oxazolidinones prevent the production of new proteins. Oxazolidinone action is unaffected by resistance to other protein synthesis inhibitors; nonetheless, there have been isolated reports of oxazolidinone resistance cases that are linked to 23S rrna changes after treatment. The first oxazolidinone to be commercially accessible, linezolid, has already replaced oxazolidinones in the treatment of Gram-positive infections. Its application for surgical infections is made possible by its pharmacokinetic qualities as well as its excellent penetration and accumulation in tissue, including bone, lung, vegetations, hemorrhage, and cerebrospinal fluid.

Inhibition of bacterial protein synthesis with example like Linezolide

The first of a new class of antibiotics called oxazolidinones is linezolid. These antibiotics work as inhibitors of protein synthesis, preventing mrna from attaching to the 30S ribosome subunit.

A bacteriostatic medication, linezolid is effective against infections brought on by gram-positive bacteria, such as MRSA, coagulase-negative staphylococci, VRE, and strains of S. Pneumoniae that are resistant to macrolides and β-lactam antibiotics. The FDA has approved the use of linezolid in pediatric patients, including those in the neonatal age range, after it was researched. Linezolid is licensed for the management of both community- and hospital-acquired pneumonia, both complex and noncomplicated infections of the skin and soft tissues, and bacteremia brought on by microorganisms resistant to vancomycin.

While the kidney gets rid of the oxidative metabolites, nonrenal processes are used to remove linezolid. When there is mild to moderate hepatic or renal insufficiency, there is no need to change the dosage. Regarding healthy youngsters receiving regulated treatment, the drug's nonselective and reversible inhibition of monamine oxidase appears to be of little therapeutic significance. However, the PICU patient taking adrenergic or serotonergic medication may be impacted by this drug interaction profile. Hematologic adverse effects including, less frequently, ocular neuritis and peripheral neuropathy have been linked to linezolid. [9]

Repurposing of Existing Drugs The process of employing an already-approved medication or medication candidate for a novel medical ailment or treatment for which it was not previously recommended is known as "drug repurposing." It was first created to address a distinct medical issue. It has been characterized as an unforeseen, serendipitous procedure.

12. Anti – Cancer Drugs :-

Cancer is a prevalent and often occurring disease that poses a major risk to human health. According to contemporary cell biology, its fundamental mechanisms include cancer stem cell reproduction, unchecked cell cycle, and aberrant cell proliferation and migration. 1. Cancer claims the lives of almost eight million people annually, severely impeding global economic and social progress. Although the term "chemotherapy" is often connected to cancer treatment, its definition is actually more expansive. Chemotherapy is the use of a particular chemical to treat a disease with the goal of identifying and eliminating its exact cause. Chemotherapy, then, is a cancer treatment that targets and destroys cancer cells using extremely particular chemicals. Treatments that aim to eradicate bacteria, viruses, and other contagious microbes are also referred to as chemotherapy. We refer to this as antimicrobial chemotherapy. Antimicrobial chemotherapy also includes antivirals, anti -parasitics, antifungals, anthelmintics, and antiprotozoals.

Millions of people worldwide still die from cancer, a disease brought on by the unchecked proliferation and spread of aberrant cells. According to estimates from the International Agency for Research on Cancer (IARC), there were 7.6 million cancer-related deaths and 12.7 million new cases of cancer globally in 2008. Antimicrobial chemotherapy finds numerous applications in the medical field. One of the main applications is infection treatment. Antimicrobial chemotherapy may be used to treat infections caused by bacteria, viruses, fungi, parasites, or other sources.[10]

13. Use of Chemotherapeutics with anti – microbial Properties

Antimicrobial chemotherapy involves utilizing medications with specific toxicity against the cause pathogens in order to treat an infectious disease. These medications' selective toxicity causes serious harm to infections while having negligible negative effects on the host. There are insufficient clinical trials and an unknown relationship between the usage of antibiotics and the risk of developing cancer. To evaluate the relationship between antibiotic use and cancer risk, we conducted a systematic review and meta-analysis of observational studies.

The most crucial tool in the fight against bacterial illnesses are antibiotics, which are antimicrobial compounds that are effective against bacteria. Generally speaking, treating patients with suspected bacterial infections involves starting empirical treatment (that is, before the availability of conclusive culture and sensitivity data), then modification after microbiology data 2 of 16 in Cancers 2019, 11, 1174 becomes accessible. Specifically, the process of separating bacteria from clinical samples provides data that might be utilized to direct the choice of suitable regimens according to past understanding of bacterial sensitivity to specific antibiotics

14. Non – Antibiotics Adjuvants

1. Adjuvants for Antibiotics :-

Using antibiotic adjuvants (see Glossary), which improve the activity of existing medications and can reduce or even completely block resistance, is an additional tactic to safeguard our present medications. 15, 14, 16, 17. Adjuvants are combination medications since they are administered in conjunction with antibiotics . The efficacy

of antibiotic combinations (antibiotic A + antibiotic B) in the clinic serves as a model for the idea of antibiotic adjuvants 17, 18. These have been used for.

Drugs enhancing the efficacy of existing antibiotics Given that one of the main causes of the levels of antibiotic usage is the ineffectiveness of present treatments for bacterial illnesses, such intervention is required. Despite bacterial strains being proved in many instances to be responsive under in -vitro settings to the antibiotics being treated, high doses ,for extended periods, and often with many different medicines, are often essential.

Antibiotics can be made more effective in a variety of ways, such as: -

1. Taking antibiotics with additional medications:- For instance, amoxicillin trihydrate and potassium clavulanate together can make amoxicillin more effective against amoxicillin-resistant cells.

2. Employing inhibitors of enzymes :-Antibiotic-ineffective microorganisms that manufacture enzymes resistant to treatment can be treated using enzyme inhibitors. To increase the potency of other antibiotics, clavulanic acid, for instance, is a broad-spectrum β-lactamase inhibitor that can be used with them.

3.Using inhibitors of the efflux pump :-Since bacterial resistance is mostly dependent on efflux pumps, blocking them can make antibiotics more effective again.

4. Using antimicrobial peptides :-Antibiotics against resistant strains can be more effective when antimicrobial peptides break down bacterial cell membranes.

5. Using lipid polymer hybrid nanoparticles:- Antibiotics such as vancomycin or doxycycline can be encapsulated in these nanoparticles to increase their antibacterial efficacy.

6. Making use of compounds generated from antibodies :-
Because these compounds can be designed to target a broad variety of bacteria, fewer particular antibodies are required for each infection.

15. Combination Therapies

Using many antibiotics to treat a single infection is known as combination therapy. It is frequently used to treat infections that are hard to cure, grow slowly, or are drug-resistant.

1. Methodology for literature searches :-This evaluation is based on Pubmed and Medline searches for articles published between 1930 and 2019 that used the keywords "combination therapy" and "antimicrobial resistance," along with other pertinent allusions to what we know.

3. AMR :-Three Critical Priority bacteria have been identified by the World Health Organization (WHO): Pseudomonas aeruginosa (CRPA), Enterobacteriaceae (CRE), and Acinetobacter baumannii (CRAB) resistant to the majority of other penicillins and carbapenems . There is growing opposition to the "last Colistin is a "resort" antibiotic . Just six businesses have medications undergoing clinical studies that may eliminate each of the three infections and five of these treatments have only advanced to Phase I or II testing. Additionally, The approval of less than 20% of all antibiotics completing Phase I trials will result in significant research expenses for medications that are never put on the market.

4. Combinations of Antibiotics :-"The bundle of twigs is strong, but one twig breaks." Tecumseh (1768–1813).A year prior to the introduction of penicillin, Staphylococci that were resistant to the antibiotic had already surfaced utilized in clinical settings demonstrates that germs are constantly one step ahead. For more than 70 years, the creation of antibiotics and their subsequent application in therapeutic settings to treat bacterial infections has primarily been fueled by the discovery of monotherapy. Significant deviations from the monotherapy Antibiotic combination therapy is the "rule" for treating bacterial illnesses like Mycobacterium tuberculosis.

5. Cooperation

In vitro, the combined therapeutic effect of several antibiotics is larger than the sum of their individual effects. Vancomycin's ability to effectively combat E. Coli when coupled with either nitrofurantoin or trimethoprim. Due to the abundance of antibiotics available on the market and nearly infinite combinations, there is a great deal of potential for medicinal benefits from this phenomenon.

Combination therapy, nevertheless, can potentially be detrimental to patients. Antimicrobials interfering with each other's metabolism and effect, higher costs, increased complexity in administration, and an increase in adverse drug responses are a few possible drawbacks.

Additive, synergistic, and antagonistic effects are combination therapy's three primary outcomes:-

1] Additive: The total effect is the same as the sum of the parts.

2] Synergistic: The total effect of the individual effects is exceeded by the combined effect.

3] Antagonistic: The combined effect is smaller than the sum of the individual effects.[11]

1.Synergistic Drug Combination

Antibiotic synergy is a precisely defined microbiological phenomenon that requires two bioactive drugs to have increased antibacterial activity when combined. Combination therapy is frequently utilized in the clinical setting due to the rise in antibiotic resistance and the scarcity of new medications to treat germs that are resistant to several antibiotics. Before being employed therapeutically, these combinations frequently showed synergistic activity in both in vitro and animal models.

16. Combination of Drugs to Overcome Resistance :- A new class of cancer medications known as "targeted therapy" is made to block a particular molecular target, usually a protein, thought to possess a vital part in the development or spread of tumors (Scaltriti and Baselga, Baselga and Arteaga, 2005; 2006). The effectiveness of clinical Tyrosine kinase inhibitor (TKI) imatinib, a small chemical In chronic myeloid leukemia (CML), mesylate (Gleevec®) and GIST (gastrointestinal stromal tumors) has been proven to An approach to treating tumors whose growth is vitally reliant on certain kinase targets Antibiotics tamper with DNA by changing cell membranes, blocking the function of enzymes, and stopping mitosis. When acute lymphocytic or granulocytic leukemia is resistant to standard anticancer medications, daunorubicin is primarily employed. It can ensnab DNA and prevent RNA and DNA production, but because of its brief remission time, it must be taken in combination with other medications. Niclosamide and daunorubicin work in concert to increase ROS levels and inhibit the NF-κb pathway. Since many prostate cancers are androgen-dependent, anti-androgen therapy is crucial. It is commonly recognized that radiotherapy, chemotherapy, and targeted medications (such as anti-androgens) cause prostate cancer cells to differentiate into brain cells. These differentiated cells are resistant to therapy and lack prostate-specific antigens and androgen receptors.

17. Beta – Lactams with Beta – lactamase Inhibitors :-

Health care was altered by the 1928 discovery of the β-lactam penicillin and the subsequent development of additional antibiotics throughout the following decades. However, the pipeline for new therapeutic development has all but dried up today. In addition, the need for new antibiotics has resurfaced due to the persistent evolution of drug-resistant bacteria and the real possibility of incurable bacterial infections. New antibiotics with novel targets and activity against both Gram-positive and Gram-negative pathogens are particularly needed. Not only were the β-lactam antibiotics among the first to be discovered, but its scaffold has undergone the most successful diversification in nature and the pharmaceutical industry, making them the medication family that is most frequently employed to treat infections. Due to the β-lactams' special status and the resemblance to other serine proteases and bacterial penicillin-binding proteins (pbps), their targets.

One of the most significant classes of medicines for humans, β-lactam antibiotics work by inhibiting penicillin-binding proteins (pbps). The development of these compounds as inhibitors of additional targets has been spurred by their unmatched performance. Although bacterial type I signal peptidase and pbps are related evolutionary,

inhibition of the former may need β-lactams with 5S stereochemistry, rather than the 5R stereochemistry of conventional β-lactams, based on the catalytic mechanism and substrate stereochemistry.[12]

18. Anti-Virulence Approach

1. Quorum Sensing Inhibitors :- The ability of these quorum sensing inhibitors (qsis) to competitively inhibit the QS signaling pathway presents a chance to create novel medications that target these targets in order to fight infections. The main focus of this review is on synthetic and natural qsis that target various QS components and their possible usage in medical domains. Finding a system with the potential to be used in managing bacterial infections while avoiding bacterial cell stress and thereby reducing the importance of antibody formation is the main goal.

2. Blocking bacterial communication to reduce pathogenicity :- One of the biggest global health issues, infectious diseases have a profound effect on society. For example, respiratory infections rank third in terms of causes of mortality and account for about 3 million fatalities annually . Vaccination and antibiotic therapy are traditional techniques of controlling these infections. These measures have emerged as the best defence against infectious diseases, improving the quality of life and life expectancy of the affected population.

This is a summary of the largely conserved general mechanism of QS signaling. The analogous synthase enzymes in bacteria first create ais, which they then secrete into the extracellular medium. Ais are either actively or passively internalized through the bacterial membrane to bind to the cytosolic or trans membrane receptor controlling the expression of hundreds of genes once an external AI threshold concentration is achieved (this depends on the density of the bacteria) .[12]

2.Biofilm Inhibition :- Complexes of bacteria known as biofilms, which stick to surfaces and release extracellular matrices that provide protection, have a significant impact on a variety of fields, including environmental research, industry, and medicine. Even though biofilms continue to provide difficulties in clinical medicine, research in this area is still continuing and uncertain. In order to document the changing field of biofilm research, this article offers a current evaluation of biofilms and their management, emphasizing recent developments. Since polysaccharides, proteins, and nucleic acids (e-DNA) make up the majority of the EPS matrix of biofilm, attacking the biofilm matrix is one method of biofilm suppression. By causing the EPS matrix components to become disrupted, the biofilm can degrade.

In particular, a biofilm can tolerate stresses like fluid shear and mechanical pressure because of its extracellular polymeric substance (EPS) matrix, which is made up of proteins, polysaccharides, extracellular DNA, and lipids. It was discovered that in staphylococcal biofilms, higher mechanical pressure promoted the biofilm's EPS to create more polysaccharides, even though greater EPS production can only be hypothesized for environmental difficulties like fluid shear.

The microbial strain, age, and additional environmental variables including ph, oxygen tension, and nutrient abundance all affect the components of the biofilm extracellular polymer matrix (EPS) (Flemming & Wingender, 2010).

1. The way biofilm diseases are now managed and treated :- The cohesiveness of microorganisms that form biofilms produces an extracellular matrix on its own, creating conditions that encourage bacterial tolerance and antibiotic resistance through a variety of mechanisms that depend on variables like the composition of the biofilm and the growth environment. Drug penetration across the biofilm barrier has been the subject of numerous investigations, although the underlying mechanisms are still unclear. Therefore, it is essential to comprehend the mechanisms by which biofilms contribute to antibiotic resistance and tolerance in order to develop novel approaches to treat these illnesses.

2. Structure penetration and density :- The ability of the antimicrobial agent to pierce the heterogeneous biofilm structure is correlated with the effectiveness of biofilm therapy. It has been demonstrated that the genus and strain of bacteria, the antibiotic chosen, and the biofilm structure all have a significant impact on the drug's ability to penetrate the biofilm (Singh et al., 2016). It has been shown that extracellular DNA, which makes up the biofilm's structural scaffolding, causes antibiotic resistance.



Figure 1: The developmental phases that lead to the production of bacterial biofilms

Strategies to biofilm and enhance antibiotics effectiveness :-

It has also been demonstrated that increased antimicrobial lipid concentrations may be effective in eliminating biofilms. Lipid-coated hybrid nanoparticles were used in a similar investigation to improve antibiotic treatment-associated biofilm penetration.

Furthermore, secondary metabolites like phenazines and quinolines have shown to completely eradicate some biofilms while also having low toxicity; however, it is important to note that these metabolites have also been shown, depending on the species and strain, to induce the formation of biofilm.

19. Emerging Technologies and Approaches

Radical originality (in application, if not in sources), coherence, significant influence, uncertainty and ambiguity, and relatively quick expansion are characteristics of emerging technologies. As an alternative definition, "a radically novel and relatively fast growing technology characterised by a certain degree of coherence persisting over time and with the potential to exert a considerable impact on the socio-economic domain(s) which is observed in terms of the composition of actors, institutions and patterns of interactions among those, along with the associated knowledge production processes" refers to an emerging technology. However, its greatest influence will come later, thus the emerging phase is still a little unclear and hazy.

A wide range of technologies, including robotics, artificial intelligence, nanotechnology, biotechnology, information technology, and education technology, are considered emerging technologies. [13]

20. CRISPR-Cas System in Antibiotics Resistance

A collection of CRISPR-associated (Cas) genes and a CRISPR array make up the CRISPR system. Short repeat sequences broken up by spacer sequences make up the CRISPR array. An A-T-rich leader sequence with a promoter that starts the transcription of the repeat and spacer sequences usually comes before the CRISPR array. This review tries to provide new ideas for the prevention and control of bacterial resistance by describing the structure and mechanism of the CRISPR-Cas system, introducing the

delivery method, clarifying the relationship between CRISPR-Cas and antimicrobial resistance, and discussing the current state of clinical challenges. Overall, various bacteria respond differently to CRISPR-Cas systems in terms of antibiotic resistance. One significant tool in stopping the spread of antibiotic resistance is the CRISPR-Cas system.

21. Target gene removal

Gene knockouts, sometimes referred to as gene deletion or gene inactivation, are a popular genetic engineering method in which a single gene within an organism's genome is intentionally removed or rendered inactive. Numerous techniques, such as homologous recombination, CRISPR-Cas9, and talens, can be used to do this.

22. Using CRISPR technology to delete resistance genes

Prokaryotes use CRISPR/Cas9 as an acquired immune system to combat plasmids and phages. CRISPR RNA (crrna) and trans-activating crrna (tracrrna) coordinate Case's DNA binding and nuclease activity. Through complementary base pairing, a sgrna in CRISPR/Cas9-mediated genome editing identifies its target sequence (protospacer) in the genome.
While the growth of all CRISPR-expressing strains was similar, all strains that harbored spacers against the plteto-1 promoter showed significantly less Gfp fluorescence in contrast to a non-targeting spacer control. Both plasmid and chromosomal targets were successfully silenced with comparable effectiveness Gfp Repression was noticeable early on in the growing process, although we utilized a time point in exponential development that was three hours after induction. Phase, to measure the fluorescence change .[14]



Figure no :1 Schematic diagram of CRISPR/Cas9 mechanism

23. Phage Therapy

In phage therapy, bacteria are killed by viruses known as bacteriophages, or phages, as a means of treating bacterial illnesses.

A. Mechanism :- Use of Bacteriophages to target specific bacteria

Twort and Lond1 and d'Herelle2 separately identified bacteriophages as transferable, bacterial lysis agents. At first, they were believed to be essential for managing bacterial infections. However, preliminary research was mainly ineffective. Bacteriophages can infect the majority of procaryotic collections of organisms that have been separated and are easily separated from water, sewage, soil, and, as may as anticipated from the majority of habitats inhabited by bacteria. Phage diversity in the ecosystem is as diverse and as adaptable as their hosts, some of which can endure temperature fluctuations up to 95°C and variations in ph as low as Once connected, it breaks through the cell wall and draws the bacterium's DNA inside, thus seizing control of the cell and preventing it from reproducing or functioning.

As necessary parasites, phages can integrate genetic material into the bacterial chromosome without causing cell death (lysogenic pathway) or cause cell lysis to release newly formed virus particles (lytic pathway) upon multiplying by seizing control of the host protein synthetic machinery. Strictly lytic phages are relevant from the standpoint of food safety because they attach themselves to the cell wall of the host bacterium when a bacteriophage attacks it.

When bacteriophage replication weakens the structure of the cell wall and fills up all of the space inside the bacterium cell, the cell wall bursts (lyses), releasing new bacteriophages into the surrounding environment to further infect any bacteria that may be present (Sillankorva et al., 2012).

B. Phages have a number of benefits:

• Bacterial cell wall receptors determine the high host specificity, ignoring the rest of the microbiota.

• self-replication and self-limiting, which means that as long as a host threshold is still in place, low or single dosages will multiply

• low intrinsic toxicity because they primarily include proteins and nucleic acids

• optimal "survival" (including physiochemical parameters) during food processing. [15]

24. Antimicrobial Peptides (amps)

Short, positively charged molecules called antimicrobial peptides (amps) are a component of the innate immune system and exhibit a wide spectrum of antimicrobial activity. The majority of the modern, conventional antibiotics are no longer effective against bacterial infections Consequently, developing new pharmaceutical antibiotics as a substitute to manage and cure the infections brought on by these pathogens is crucial.1–4. Antimicrobial peptides (amps) have garnered interest in this context as a viable option that may be isolated from natural sources and utilized against germs that are resistant to antibiotics. There are 5–7 amps in all living things, including bacteria, plants, vertebrates, and invertebrates. They have broad-spectrum antibacterial properties characteristics that protect against a broad range of viruses, bacteria, fungi, protozoa, and—surprisingly—even malignant cells. In Furthermore, amps exhibit immunomodulatory properties that are crucial in adaptive immunoregulation and inflammatory reply.

B. Mechanism :- Disruption of bacterial membranes by natural or synthetic peptides

The targeted cells will either undergo necrosis or apoptosis, depending on the distinct modes of action of the peptides. According to the barrel-stave model, when amps attach to the cell membrane's surface, their hydrophobic groups become buried and create a pore structure, which causes the contents of the bacteria's cells to overflow and eventually kill the cells. In the carpet model, amps alter the bacterial membranes' surface tension, causing the membranes to distort and ultimately cause the cell membranes to disintegrate.

The third concept, known as the toroidal-pore model, describes how amps clump together, penetrate bacterial cell membranes, and alter the phospholipid monolayer of the bacteria until a ring hole that is between one and two nano meters in diameter forms, eventually leading to the death of the bacteria. The aggregated channel model is the final model. According to this hypothesis, amps are thought to attach to the phospholipid molecules on the cell membrane surface, create peptide-lipid polymers, and then enter the cells, killing the bacteria illustrates the many action models of the membrane permeability mechanisms.[16]

25. Nano- technology in Drug Delivery

Conventional antibiotics have a number of drawbacks, including i) resistance developing over time, ii) low therapeutic index, iii) cytotoxicity and advers effects, and iv) non-specific mode of action of action and v) an awkward administrative path, although These issues can be partially resolved by employing various techniques for delivering antimicrobials that use nanotechnology It describes the creation, manufacturing, and use of materials at the nanoscale (1--100 nm). Their distinct physical characteristics and chemical characteristics (high surface-to-volume ratio, tiny size) & suitable for surface alteration) could be used as trucks to transport different medicinal or diagnostic substances to overcome the majority of physiological obstacles and obtain biologic compounds and their intended targets.

Among the difficulties posed by nanotechnology in medicine distribution are:-

1. Ensuring that medication expression occurs only in the intended organs
Knowing what happens to medications once they enter cells and organelles

2. Adjusting medication dosages to reflect nanotechnology's greater efficiency

3. Taking toxicity issues seriously

4. Guaranteeing availability of medication delivery systems based on nanoparticles

A. Targeted delivery

Targeted delivery is the effective administration of a therapeutic drug and it’s pre dominate accumulation in a desired location. The agent-laden system should escape the immune system, target a particular cell or tissue, and release the loaded therapeutic drug after spending the optimal amount of time in the physiological system.

B. Nanoparticles for targeted antibiotics delivery to infection sites

At the moment, targeted nanoparticle delivery is being researched extensively for cancer therapy. More than twenty percent of therapeutic nanoparticles that are currently being evaluated clinically or in clinics were created with anti-cancer purposes in mind. Furthermore, related research has concentrated on the use of nanoparticles in the treatment of various other illnesses, including autoimmune, neurodegenerative, and viral diseases.[17]

26. Alternative Approaches to Combatting Resistance

Over many decades, a variety of antimicrobials have been created and put on the market with the shared goal of treating and curing mild to severe infections. A variety of antimicrobials, including several improvements on the revolutionary antibiotic penicillin itself, were discovered as a result of the accidental discovery of penicillin in the late 1920s. New antiviral medications have also been developed as a result of research to treat diseases like AIDS that were previously incurable. Antifungal (sometimes called anti-mycotic) and anti-parasitic drugs have also become important instruments in the fight against infection.

Although the development of the phenomenon known as antimicrobial resistance (AMR) in reaction to antimicrobials has significantly reduced the usefulness of these antimicrobials, they have been crucial in enhancing our health and life expectancy. Researchers are now forced to concentrate on novel antimicrobial

therapies that are distinct from conventional antibiotics because the problem of antibiotic resistance has worsened due to the delay in the discovery of new medicines.

Antimicrobial peptides, phage treatment, efflux pump inhibitors, antibodies, and immunomodulatory drugs are examples of alternative therapeutics that have surfaced in recent years and shown encouraging outcomes in both laboratory and clinical trials.[18]

27. Vaccine Development

Vaccines and antibiotics have advantages and consequences that complement each other. Antibiotic discovery has been regarded as one of the greatest advancements in science and medicine in the history of humanity. Antibiotics have been and will continue to be crucial for the management of infectious bacterial illnesses. The majority of antibiotics have the benefit of having a broad range of impacts on several bacteria, which is in certain ways crucial in cases where the infection's causal agent is not well understood, especially when superinfections with There are several kinds of bacteria. The process of converting a novel antigen or immunogen discovered during research into a finished vaccine that can be assessed through preclinical and clinical studies to ascertain the vaccine's safety and effectiveness is known as vaccine development.

28. Challenges

Penicillin, commonly referred to as a "wonder drug" with amazing therapeutic properties for bacterial infections, especially those caused by Staphylococcus and Streptococcus species, was discovered by Sir Alexander Fleming in 1929.
Antibiotic resistance emerged shortly after penicillin began widely used in 1940, and over 95% of Staphylococcus aureus isolates found globally are today penicillin-resistant.

29. Developing Effective Vaccine Against Multi –Drug Resistance Bacteria

It is difficult to create vaccinations that effectively against multidrug-resistant microorganisms (MDR), however there are a few interesting strategies that show promise:
Reverse vaccination :-

1. With the use of bioinformatics, conserved antigenic targets that offer defense against newly emerging drug-resistant bacteria can be found.

2. Multiple epitope vaccinations

3. These vaccines might be created more quickly and can have several antigenic targets.

4. Membrane antigen-specific generalized modules (GMMA)

5. It is possible to genetically modify these outer membrane vesicles to increase their capacity for protection.

6. Adjuvants Innate immune receptors can be targeted by adjuvants such as AS01, which may aid in preventing the reactivation of tuberculosis.

The following are some obstacles to creating vaccinations against MDR bacteria:

>The challenge of choosing potential bacterial antigens
>The pathogenic bacteria's varied temporal sequences and pathogenesis pathways

>The declining effectiveness of conventional vaccinations against newly developing germs resistant to antibiotics .[4]

30. Probiotics and Microbiome Therapy

Probiotics :- Live bacteria and yeasts, or probiotics, are good for your health. Your body already harbors these and numerous other species. Probiotic pills replenish your body's natural supply of beneficial bacteria. They strengthen your immunity against illnesses and assist in warding off the less cooperative varieties.

1. The importance of probiotics –
Probiotics are live microbial strains that, when given to the host in sufficient quantities and in a viable state, may have positive health effects. Nobel laureate Elie Metchnikoff was the first to propose the idea of probiotics to the scientific community. These microorganisms have the capacity to regulate gut microbial populations and preserve the equilibrium of the intestinal microbiota ecosystem. Probiotics ought to be "widely record.

2. Probiotics' function in maintaining gut microbiota balance-
Numerous positive health consequences are linked to the gut microbiota's (GM) balance. Microbial diversity has been directly linked to GM's ability to revert to an equilibrium state in response to chemical (diet, antibiotic), physical (ph, changes in intestinal passage rate), or microbial (probiotic supplements, fecal transplants) variables. It might be feasible to restore GM equilibrium by i) giving probiotic microorganisms, which replace dangerous.

3. By altering the microbiota, probiotics can help treat and manage cancer-Probiotic strains are widely recognized for their positive impacts on inflammation, the immune system, human health, and a number of conditions unique to the digestive tract. One of the most crucial elements for preserving proper homeostasis is the gut microbiome. The gut microbiota is significantly impacted by probiotics. Fermented dairy products are the primary source of probiotic microorganisms.

4. Probiotics in the treatment of colon cancer-
Due to the involvement of GM, gut homeostasis, intestinal microbial pathogens, carcinogens, intestinal epithelial integrity, and other factors impacting the gut milieu, probiotic research has become crucial in cases of colon cancer. According to research, taking probiotics on a daily basis may enhance the gut microbiota's composition, which may lessen chronic inflammation and the synthesis of carcinogenic substances.

5. 5.Probiotics' function in breast cancer treatment –
Probiotics' potential to prevent breast cancer has been the subject of numerous in vitro and animal research. By stimulating the production of pro inflammatory cytokines like IFN-γ and inhibiting the production of anti-inflammatory cytokines, a trial that included oral administration of Lactobacillus acidophilus (at a specific dosage) showed a significant improvement in immune responses.

31. Microbiome Therapy :- By applying native or synthetic bacteria, antibiotics, bacteriophages, and bacteriocins, microbiome treatments seek to modify the gut microbiome through additive, subtractive, or modulatory therapy.

1. The various functions of gut microbiota - Cognitive development, emotional and temper regulation, communication styles, interpersonal relationships, and neuro-immune integration for neuronal differentiation, axonal growth, and synaptic plasticity are all significantly influenced by the gut microbiota . The bacteria, fungi, viruses, and other microorganisms that are present in the digestive tract are in a state of dynamic equilibrium and reciprocal connection.

2. Factors influencing the formation of microbiota -
Although the gut microbiota (GM) is a well-organized focal ecosystem, the bacteria' makeup is changing. Through a variety of strategies, such as direct killing, competition for scarce nutrients, and boosted immune responses, gut microbiota can prevent pathogen colonization. In the human or mouse digestive tract, intestinal microorganisms can change the expression of several genes related to immunity, nutritional absorption, energy metabolism, and intestinal barrier function.

3. Factors influencing gut microbiota stability - Under normal conditions, the presence of the mucus layer, tight junction proteins, immunoglobulin A, antimicrobial factors, and guard cells—intraepithelial lymphocytes and adaptive immune cells—maintains an effective gut barrier inside the gastrointestinal system. The immune system

and gut bacteria interact in a variety of ways through several signaling pathways that aid in the control of lipid, glucose, and energy metabolism.

4. Reasons why the gut microbiome is out of balance -In addition to maintaining the microbiota's makeup, the human intestinal microbiota aids in the digestion and synthesis of organic acids and short-chain fatty acids (scfas), such as propionate, acetate, and butyrate. For the host and microbiota to cohabit in a mutually beneficial relationship, the gut microbial population must be in equilibrium. Dysbiosis results from the loss of mutualistic relationships between the host immune system, metabolic products, and microbiota members in a microbial ecosystem.[19]

32. Mechanism: - Using Probiotics to Outcompete Pathogenic Bacteria and Restore Microbiome

Probiotics are defined as "living microorganisms, which when administered in adequate amounts confer health benefits on the host" by the World Health Organization and the Food and Agricultural Organization of the United Nations.

The gastrointestinal tract of humans contains probiotic systems. Probiotics have the ability to control the microbial populations in the gut and hinder the growth of infections by stimulating the synthesis of iga and β-defensin in the host. Probiotics have the potential to strengthen the intestinal barrier through the preservation of tight junctions and stimulation of mucin synthesis. The regulation of intestinal microbial communities, immunomodulation, pathogen suppression, promotion of epithelial cell proliferation and differentiation, and intestinal barrier fortification are some of the mechanisms of probiosis.

1.Straightforward mechanism -
Bacteria engage in direct mechanisms of colonization resistance, with the host serving as the setting for competition. In the gut (Fig. 1) and outside the gastrointestinal tract (Box 2), bacteria can directly prevent one another's growth by either creating inhibitory chemicals (referred to as "interference" competition in ecological terms) or by vying for resources (referred to as "exploitative" competition). The majority of the nutritional resources in the gut are supplied by the host, either through food consumption or secretions like mucus. Other gut-dwelling microbes also contribute additional nutrients.



Fig. 1 | Direct mechanisms of colonization resistance.

Native symbiotic bacteria starve the pathogen of vital nutrients and molecules by consuming dietary amino acids (aas), carbohydrates, metals, and respiratory electron acceptors like O2 and NO3- (left panel). Bacteria can alter host glycosylation at the epithelial surface and/or exploit it as an adhesion nutrient, forming a novel microscopic niche that prevents pathogens from reaching the epithelium. Pathogen access can also be blocked by other symbionts clinging to mucus or epithelial locations. Additionally, symbionts can directly eliminate pathogens through the type VI secretion system (T6SS), contact-dependent inhibition (CDI), or secreted compounds such pheromone peptides or bacteriocins (centre panel). [20]

33. Immune Modulation

The process of altering the body's immunological response to infections and foreign substances is known as immune modulation.

Therapeutic Approaches

1. Phenolic antimicrobials
2. Antisense antibacterial medications
3. Prebiotics
4. Peptides that defend hosts
5. Metal compounds and ions
6. Antibody treatments

1.Bone remodeling and resorption :-

Erythromycin can prevent inflammatory osteoclastogenesis brought on by wear debris by lowering the generation of cytokines and osteoclast differentiation in part through nfκb signaling down-regulation, which could make it helpful for the treatment and avoidance of aseptic joint deterioration.

2.Inflammatory intestinal illness :- Acetic acid-induced colonic inflammation was considerably (pb0.05) decreased by administering either erythromycin or azithromycin harm in rats (an inflammatory colitis model) by lowering activities of nitric oxide synthetase and myeloperoxidase, in addition to (Mahgoub et al., 2005) TNF-α level. People who have Crohn's 200 mg of clarithromycin twice a day was used to treat the condition. Eight (57.1%) of the 14 participants demonstrated clinical improvement, while five of the eight (35.7%) saw clinical Remission.

3. Arthritis and connective tissue disease :- In a rabbit model with aseptic temporomandibular joint, the immunomodulatory effects of erythromycin were investigated rabbits' irritation of the space. Two hours following the administration of Carrageenan and either erythromycin or saline were administered into the right temporomandibular joint. Histopathologically and scintigraphically, the joints of the animals that received treatment showed decreased inflammation with erythromycin .[21]

34. Using monoclonal antibiotics and immune – boosting drugs to enhance the immune respose

Probiotics are advantageous, living microorganisms that invade the human intestine and alter the flora's composition in specific areas of the host. The use of probiotics to control gut flora and enhance host immunity has gained a lot of interest lately. According to recent research, probiotics have a major impact on the makeup of the gut microbiota, which can help the host create a protective layer of healthy intestinal mucosa, improve the host immune system, and prevent the colonization of pathogenic bacteria in the intestine.

Because human immunity and the gut microbiota are closely related, controlling the gut microbiome with probiotics has emerged as a highly successful strategy for enhancing immunity in humans. In this review, we covered the impact of probiotics on human immunity as well as the connections between probiotics, gut microbiota, immunity, and quality of life.

1.Monoclonal antibodies' potential for therapeutic use :-
Monoclonal antibodies have a number of properties that may make them an excellent choice for treating infections that are resistant to antibiotics, especially those brought on by Gram-negative bacteria that are resistant to numerous drugs. First, surface-exposed antigens or released toxins that are not targets of currently utilized antimicrobials are usually the targets of antibacterial monoclonal antibodies. Therefore, current resistance mechanisms are unlikely to impact the effectiveness of monoclonal antibodies.

2. Finding targets for the creation of monoclonal antibodies :- Monoclonal antibodies for the therapy of multidrug-resistant Gram-negative bacteria are probably going to target antigens that are exposed on the surface of bacterial cells, like outer membrane proteins and surface polysaccharides, in the absence of disease-defining exotoxins. Potential surface antigens include the following qualities that would make them desirable: (i) antigens found in the majority of circulating strains of a bacterial species; (ii) antigens that are largely conserved between.

3. Monoclonal antibodies to combat Gram-negative infections that are resistant to many drugs Several monoclonal antibody-based treatments are presently being developed to treat infections that are resistant to numerous drugs. Some of these antibodies have been assessed in early-stage clinical studies, while the majority are still in preclinical development. The following is an overview of current advancements in therapeutic monoclonal antibodies that have been documented for some of the most concerning antibiotic-resistant infections brought on by multidrug-resistant Gram-negative bacteria[22]

35. Case Studies and Success Stories

In this review, we have chosen 14 success stories that highlight the significance of microbiome research in developing the agrifood system, out of the numerous case studies based on microbiome applications that have been published globally. The chosen case studies outline goods, techniques, instruments, applications, and procedures that had an effect on the economy and society. The management of diseases and suspected pathogens; the use of microorganisms as plant strengtheners and soil fertilizers; the study of microbial dynamics during food fermentation; the presence of microorganisms and/or genes linked to health risks for humans and animals (such as mycotoxins, spoiling agents, or pathogens) in feeds, foods, and their processing environments; applications to enhance HACCP systems; and the analysis

A case study can include additional information regarding the company's implementation of the solution in addition to the setting, problem, and solution that the client encountered.

Success stories can be more technical than case studies, but depending on the audience you're attempting to reach, case studies might not be superior.

Although "success story," "client story," and "case study" are frequently used synonymously, a "story" and a "study" are not the same thing. A success story narrates the client's experience from the beginning—beginning with the problem that the client had to solve—through the solution and the result.

We present a summary of microbiome-based agrifood success stories in this collection of case studies that satisfy one or more of the following requirements: (i) Commercialization-related microbiome-based innovations in the context of the agrifood chain; (ii) industry-based mitigation strategies to improve product yield and quality or reduce production-related financial losses; (iii) agrifood-related microbiome-based innovations that improved plant, animal, and human health; (iv) microbiome-based knowledge that resulted in improved food safety management systems; or (v) legal regulations amended in light of microbiome research.[23]

36. Colistin as a Last Resort Drug

The objectives of these activities are to raise public awareness of antibiotic resistance and to promote effective strategies for halting its emergence and spread.

The World Organization for Animal Health (OIE) and national veterinary reference laboratory for antibiotic resistance is the Animal and Plant Health Agency (APHA).

Combating antimicrobial resistance (AMR) is a top issue for the entire world. APHA works to identify and manage threats from exotic and endemic bacterial diseases, and the growing antibiotic resistance poses a risk to human and animal health.

Monitoring antibiotic-resistant illnesses is essential for identifying patterns, origins, and the emergence of novel resistance, as well as for guiding the development of suitable treatment.

We would like to provide some information about how APHA scientists make new discoveries and the value of international cooperation in our research.

A. Mechanism :- Use of Colistin for multi – drug resistant infection , challenges with toxicity and resistance

Bacillus polymyxa produces the polycationic peptide antibiotic known as colistin (Polymyxin E), which was identified in Japan in 1949. It is an antibiotic that is part of the polymyxin class and has both lipophilic and hydrophilic qualities.

The European Medicines Agency (EMA) classifies colistin as an antibiotic that is extremely important for use in human medicine (Category B—"Restrict"). This indicates that in order to lessen the risk to the public's health, its use in veterinary care should be restricted.

Positively charged colistin L-diaminobutyric acid attaches itself electrostatically to the negatively charged phosphate groups of lipid A, a crucial part of the lipopolysaccharide (LPS) that Gram-negative bacilli produce.

When it comes to bacterial permeability and interaction with the cell outside, lipid A is essential. Colistin disrupts the three-dimensional structure of LPS by competitively displacing the divalent cations of magnesium (Mg2+) and calcium (Ca2+).
Upon inserting its hydrophobic terminal acyl fat chain, colonistin causes the exterior membrane (OM) monolayer to expand. As a result of OM's permeabilization, colistin can propagate itself across OM. This mechanism explains the synergy between colistin and other hydrophilic antimicrobials as gentamicin, b-lactamics, rifampicin, meropenem, and tigecycline.[24]

37. FDA – Approval Antibiotics Combination

Antibiotic resistance in bacteria is a persistent issue that is acknowledged on a global scale. There is a constant need for new antibacterial medications, and recent research and development efforts have produced a small number of new medications or combinations of medications that have been suggested for use in clinical settings. The innovative antibacterial agents approved by the US FDA in the recent two years (2018–2019) are the main topic of this review.

1.Plazomicin
The semisynthetic aminoglycoside bactericidal antibiotic medication plazomicin sulfate (Zemdri) works similarly to other aminoglycosides by inhibiting the 30S bacterial ribosomal subunit. It is noteworthy that plazomicin is resistant to the activity of aminoglycoside-modifying enzymes, although other aminoglycosides can be rendered inactive by these enzymes18.In June 2018, the FDA approved plazomicin to treat complex urinary tract infections (cutis) caused by Gram-negative aerobic bacteria. In June 2018, the European Medicine Agency (EMA) received the application for review.Plazomicin is used in patients over 18 who have cutis (including pyelonephritis) brought on by susceptible Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Enterobacter cloacae. It is mostly effective against Gram-negative aerobic bacteria (such as those in the Enterobacteriaceae family) and is given intravenously (IV) every 24 hours for 4–7 days. The amount of plazomicin that is delivered in single-dose vials is 500 mg/10 ml plazomicin base19.

2.Eravacycline
A tetracycline-class antibacterial drug, eravacycline dihydrochloride (Xerava) is a fully synthesized bacteriostatic fluorocycline that binds to the 30S ribosomal subunit of bacteria. The antibiotic works on particular strains of

both Gram-positive and Gram-negative bacteria that often exhibit tetracycline-specific resistance mechanisms because it has two structural modifications that set it apart from other tetracyclines. Notably, in the presence of certain beta-lactamases, eravacycline can be employed to target Enterobacteriaceae (at least in cell culture).Eravacycline was authorized by the FDA in August 2018 and the European Medicines Agency in September 2018 for use in treating complex intra-abdominal infections.

3.Sarecycline
Sarecycline hydrochloride, also known as Seysara, is a novel tetracycline derivative with a restricted spectrum. It demonstrates antibacterial efficacy against pathogens of the skin and soft tissues, such as Cutibacterium acnes, an anaerobic Gram-positive bacterium linked to the development of acne. Like other tetracyclines, it has anti-inflammatory properties. In contrast to other tetracyclines, it possesses certain unique characteristics: It exhibits a decreased rate of resistance to erythromycin-resistant and clindamycin-resistant strains of Cutibacterium acnes, as well as tetracycline-resistant Staphylococcus aureus, suggesting that it has less of an impact on the gut flora. Sarecycline significantly reduces inflammation in lesions. On noninflammatory acneiform lesions, it was observed to have statistically significant effects at specific time points.[25]

4.Omadacycline
A member of the tetracycline class, omadacycline (Nuzyra) is an aminomethylcycline antibiotic. The 30S bacterial ribosomal subunit is inhibited. Omadacycline's structural changes at the C9 and C7 positions of the core tetracycline rings, in contrast to those of other tetracycline antibiotics, allow for ribosomal defense mechanisms and stability in the efflux pump associated with tetracycline antibiotic resistance.The EMA has not yet approved omadacycline, which was approved by the FDA in October 2018 for the treatment of acute bacterial skin and skin structure infections (ABSSI) and community-acquired bacterial pneumonia (CABP). Both IV and PO versions are available for once-daily administration.

5.Rifamycin
A little absorbed bactericidal antibiotic, rifamycin (Aemcolo) inhibits bacterial DNA-dependent RNA polymerase by inhibiting RNA synthesis. It is the first antibiotic that uses Cosmo Pharmaceuticals' Multi Matrix Technology to allow the active ingredient to be released colonically. The FDA authorized it in November 2018 for the treatment of travelers' diarrhea caused by non -invasive strains of Escherichia coli. It is to be taken orally twice daily for three days at a dose of 388 mg (2 tablets), but not when the diarrhea is accompanied by fever or bloody stools. Constipation (3.5%), headache (3.3%), abdominal discomfort (0.5%), and pyrexia (0.3%) are the most common adverse events seen in clinical trials, with 1% of patients stopping therapy as a result. For the treatment of travelers' diarrhea, Rifamycin SV-MMX was proven to be just as effective as ciprofloxacin in a randomized double-blind phase 3 research (ERASE) and to not cause bacterial resistance.

The well-known RNA-synthesis suppress or rifamycin is now licensed for the treatment of non - invasive travellers ' diarrhea brought on by Escherichia coli. For severe intra-abdominal infections (imipenem, cilastatin, and relebactam) and lung tuberculosis (pretomanid in combination with bedaquiline and linezolid), two combinatorial methods were approved.

The last antibacterial medication authorized in 2019 for the treatment of complex urinary tract infections is cefiderocol, a cephalosporin antibiotic. Lefamulin is a semisynthetic pleuromutilin antibiotic for community-acquired bacterial pneumonia. In spite of these recent advancements, the development of novel antibiotic tactics and medications is still urgently needed in order to combat bacterial resistance to antibiotics.[24]

38. Clinical Outcomes

Antimicrobial resistance's effects on the overall course and expenses of infections Antimicrobial resistance's effects on clinical .Holmberg and colleagues conducted the first formal analysis of infection outcomes and costs, and several commentators have since examined it. Everyone agrees that other risk factors frequently skew the assessment of resistance's impact on infection outcomes. Because the chances of contracting an antibiotic-resistant illness (such as previous antimicrobial medication, extended hospitalization, or admission to intensive care) are linked to a bad prognosis, such analysis is especially challenging.

However, individuals with drug-resistant germs typically have at least twice the fatality rates, hospitalization chances, and length of hospital stay compared to those with species strains that are vulnerable. Treatment effectiveness is jeopardized by rising resistance. Should an ineffective agent be selected, this might lead to the initial therapy failing, and the start of an effective therapy could be postponed for a few days until the culture and sensitivity data for a resistant organism are obtained. There may not be a viable treatment in a small number of cases (which are uncommon at the moment) if the organism is highly multiply resistant, and the options for definitive therapy may be severely restricted. In developing nations with tight funds or limited availability of second- or third-line agents, opposition to only one or
Two important medications could make the body resistant to all forms of treatment. A clinical outcome is a quantifiable improvement in a patient's overall health, functioning, quality of life, or chances of survival as a result of receiving therapy.[26]

39. Successful use of combination therapies to treat resistant infection

Antibiotic resistance is a global clinical issue that is getting worse. Multidrug-resistant bacterial infections are thought to be responsible for a growing number of deaths annually, with an estimated 35,000 people died in the US, and up to 700,000 people died worldwide. According to the Organization for Economic Cooperation and Development, between 2005 and 2030, the prevalence of antibiotic resistance to last-line defenses would double. Historically, the most effective single-agent antibiotic classes target numerous cellular targets or targets that are encoded by multiple genes called multi targeting. In order to slow the development of resistance, the multi - targeting theory of long-term antibiotic efficacy suggests that bacteria must undergo several mutations before becoming resistant to multi targeting medications. The β-lactams, which target a class of enzymes known as the penicillin-binding proteins, and the fluoroquinolones, which block two topoisomerase enzymes, are two examples of multi targeting.

Since the chosen technological method has implications for late-stage development and approval, combination medicines provide unique problems for clinical development and regulatory approval that should be taken into account in an integrated research and development strategy. For instance, a factorial trial design might not be necessary for a strategy to sensitize microorganisms to an approved antibiotic that stands alone for standard of treatment, but it might impose commercial restrictions if the drug is patented. Multiple innovative compound advancement strategies may be seen as having several potential failure spots and necessitate more involved clinical studies.

Combinations that face difficulties outside of the discovery pipeline :-
Antibacterial combinations have a substantial potential impact, but their added complexity leads to difficulties with their development, regulatory approval, and deployment in addition to their discovery. Here, we discuss new ideas and concentrate on the problems that go beyond the combination discovery pipeline. The medications must be adequately overlapped in time and space during therapy if effective pharmacological combinations are discovered. Multidrug coadministration can be made considerably more difficult by variations in pharmacokinetic and pharmacodynamic characteristics. Synthetically conjugating two or more pharmacophores to create a single chemical compound that closely ties the various pharmacophores' pharmacodynamics together is one way to meet this criteria.[27]

40. Future Perspectives and Conclusion

1. The creation of antibiotics Perhaps the most significant medical advancement of the 20th century was the clinical introduction of antibiotics. Century. Antibiotics not only treated infectious diseases but also enabled a number of contemporary medical operations, such as open heart surgery, organ transplants, and cancer treatment. A steady rebirth of interest in antibiotic research and development is being driven by legislators' recognition of the threats to human health posed by the post antibiotic era and their pledge of greater grant funding. The United Kingdom
According to the government-commissioned O'Neill research, by 2050, drug-resistant diseases will claim the lives of 10 million people annually if immediate action is not taken. Promoting early-stage drug discovery is one of the main suggestions.

2. An overview of antibiotics' history Traditional moldy bread poultices were used to treat open wounds in ancient times, and the usage of bacteria that produce antibiotics to prevent disease dates back thousands of years. Egypt, Greece, China, and Serbia around 2,000 years ago. The oldest known medical document is the Eber's papyrus, which dates around 1550 BC and lists medicinal soil and moldy bread as treatments. This was motivated by Ehrlich's research on dyes and was one of the first systematic screenings for drug development utilizing a library of synthetic chemicals. That dyed bacterial cells in a certain way. Prontosil, a sulfonamide prodrug, replaced salvarsan. Gerhard Domagk , a Bayer bacteriologist, discovered it and used it to prevent the amputation of his daughter's arm. Since the sulfa medicines were based on dyes that were used to specifically label bacterial cells, Domagk and associates were successfully carrying on Paul Ehrlich's work. [28]

41. Future Perspectives

Antibiotic resistance and a lack of novel medicines are the predictable results of our existing antibiotic development, usage, and protection practices. A major shift in strategy is required to prevent a post-antibiotic era. We have to question deeply held beliefs and presumptions. We must overcome the automatic opposition and justifications (such as "that can't be" and "that's not how we do things done") that come from questioning traditions. There are plenty of excuses. Something has to be done. Ultimately, in order to overcome resistance, we require a unified national action plan. Here, we go over seven activities and three recurring themes that are essential to addressing antibiotic resistance and antibiotics in the long run. The inevitable result of our development and use of antibiotics since their discovery is the antibiotic resistance dilemma. The future of the antibiotic resistance issue is clear if we keep creating, using, and safeguarding antibiotics in the same manner as we have in the previous 80 years.

A growing number of infections will enter a post antibiotic period, resistance will continue to develop, and our options for treatment will continue to diminish. We must think creatively and question long-held, sometimes beloved beliefs if we hope to alter the course of events and ensure that there is long-term access to effective antimicrobial treatment for diseases.[29]

42. Conclusion

The most significant medical conclusion drawn from research on the fitness costs of resistance is that, even if antibiotic use is decreased, resistant clones are unlikely to vanish. Consequently, reversibility research at both the Evidence at the individual and community levels suggests that, in the absence of antibiotic selective pressure, often resistant bacteria can endure for a very long period. This low reversibility is most likely explained by compensatory evolution, cost-free mutations, and co-selection of resistance markers. These alarming results highlight the necessity of creating new antibiotics and the significance of using antibiotics wisely to prevent the emergence of resistance.

Microorganisms will continuously continue to adapt to their surroundings if historical data is any indication of future events. Serious infections brought on by these germs and growing resistance to more recent medicines will continue to be a significant problem for practicing clinicians.
To achieve a "balance" in the fight against harmful germs, industry, academia, and the government must work together. An endeavor that will involve the simultaneous application of multiple tactics, such as improved infection control procedures, a wider and better application of current public health and preventive measures to prevent infections in the first place, and improved access to diagnostic tools that enable us to more quickly and clearly.

43. The Need for Continued Research

Significant advancements in the early detection and management of infectious infections over the past 60 years have led to an astounding decrease in the morbidity and mortality linked to these conditions. This is partly because of our increased knowledge of the pathophysiology, epidemiology, and fine molecular biological mechanisms of these diseases, but primarily because of the quick development of safe and efficient new antimicrobial treatments that can target the precise agent causing the infection and aid the infected host in getting rid of the infection under treatment. Initially regarded as truly miraculous medications, the general public did not have instant access to the

first systemic antibiotics (penicillin and sulfonamides) the general public. During World War II, these medications were initially only available to the military due to their scarcity and high cost.[30]

44. Narrow – Spectrum Antibiotics

Naturally, there are numerous obstacles to a limited spectrum approach's usefulness. The need for quick, precise, and sensitive diagnostic tests for the diagnosis of bacterial infections is arguably the biggest obstacle. Furthermore, physician education will be necessary to facilitate a cultural shift away from empirical to more customized therapy, which will be necessary for the practical acceptance of narrow-spectrum antibiotics. There are financial obstacles to the discovery and creation of new narrow-spectrum antibiotics. Naturally, a drug's market size reflects the prevalence of the condition, and by definition, the use of narrow-spectrum antibacterial treatments is more constrained than that of their broad-spectrum counterparts. Antibiotics with a narrow spectrum are effective against a particular subset of bacterial species. They are only able to affect gram +ve or gram -ve, not both. The pharmaceutical sector will need to change its perspective in order to use some antibacterial drugs. For many years, the pharmaceutical industry's efforts to discover antibiotics were focused only on the focus was on finding broad-spectrum medicines that were active against both Gram-positive and Gram-negative bacteria. Compounds that didn' t fit this criterion were filtered out of antibiotic research programs. Leads for novel narrow-spectrum or pathogen-specific discovery projects may be found in some of these previously rejected drugs. The European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have recently added antibacterial agents that are active against a narrow spectrum of mdrpathogens to a list of treatments that qualify for a quicker route to registration. This change requires regulatory changes.

Names of drugs:

1. Azithromycin.
2. Clarithromycin.
3. Erythromycin.
4. Clindamycin. [31]

45. Targets specific pathogens to minimize resistance development

Selection pressure from the antibiotic on the population of microorganisms leads to the natural occurrence of resistant strains. At the moment, there are five primary targets for antibiotics, and it is basically possible for antibiotic resistance to be exhibited by four distinct mechanisms and acquired by four distinct paths (Figure 1).The development of drug-resistant strains is accelerated by the overuse and abuse of antimicrobial medications. The World Health Organization (WHO) reports that extensively drug-resistant tuberculosis (XDR-TB) has been found in 100 countries and that there were around 480 000 new cases of multidrug resistant tuberculosis (MDR-TB) in 2013. All around the world, bacteria that cause common diseases (such as bloodstream infections, pneumonia, and urinary tract infections) have significant percentages of antibiotic resistance.

In 1947, a bacterium strain resistant to penicillin initially surfaced. Within a year after the penicillin's introduction in the clinic, two years after it became widely available, and not nearly twenty years after its discovery in 1928, four strains of penicillin-resistant staphylococci were identified from patients. Many natural compounds with antibacterial capabilities were found during the golden age of antibiotic research (1940–1970). These compounds primarily try to disrupt or kill the bacterial cell wall, cell membrane, or vital enzymes involved in protein and nucleic acid production in order to target important bacterial functions or growth processes. To reduce side effects, all of these "first generation antibiotics" work by focusing on bacterial structures that are distinct from those found in mammals.



Figure 1. The four resistance acquisition pathways, the four main mechanisms of resistance, and the five main targets for antibiotics.

To make them more effective or less vulnerable to resistance mechanisms, several have undergone rational and methodical modifications. Finding new antibiotics from natural sources is another method to increase our options for treating infections, but it does not remove the inherent risk of resistance to these new drugs. In order to address the root cause of the issue rather than merely creating more resistance down the road, a mechanistic and structural understanding of bacterial resistance has far better prospects for solving this problem. It is possible to avoid or even reduce antibiotic resistance by combining mechanistic information on resistance with logical structure-based drug development techniques.

This journal and others have published numerous thorough and high-quality review articles about antibiotics. Among other things, their attention has been on the antibiotic manufacturing and discovery, as well as the development of antibiotic resistance. We highlight structure-based strategies in this review that have been effectively used to prevent antibiotic resistance. This illustrates how widely applicable this strategy is by utilizing a variety of target classes and structure-based approaches. Our selection is mostly focused on examples that can act as showcase initiatives for the antibiotic research community and have already produced clinical therapeutic candidates.[32]

46. Challenges in development and market entry of new antibiotics

The development of new antibacterials was the consistent and effective reaction to new resistance for fifty years, from 1940 to 1990. Since resistance is growing more quickly than new antibiotics are being created, this approach has not worked in recent years.
The total number of newly approved antibiotics has decreased include a lack of novel agents to combat gram-negative bacteria. This failure is the result of multiple factors. Above all, it shows a shift by "big pharma" away from antibiotics, which have become more challenging to license and are less profitable as short-term therapies than medications for long-term illnesses.

The failure also highlights the unique difficulties in discovering antibiotics. Multiple target species that vary throughout time must be attacked by antibiotics, by resistance-building, and this needs to be done in several body parts. Since kpc and metallo-carbapenemases require very different inhibitors, even the creator of a novel b-

lactamase inhibitor (which targets bacterial enzymes rather than bacteria themselves) has to predict which will be the bigger issue in five years. Other therapeutic fields do not require this flexibility: a medication for diabetes, alzheimer's disease, or hypertension must bind a single, consistent target at a single body site, and while anti-cancer medications, such as antibiotics, are susceptible to resistance, this is not contagious across individuals or malignancies.[33]

47. Economic Barriers

Numerous scientific, regulatory, and financial obstacles have made it difficult to resurrect antibiotic research and development. But the economic problems are the ones that affect the entire value chain, seem to upset developers the most, and are exacerbated by the scientific and regulatory obstacles. This section will outline the main financial obstacles to the development of new antibiotics and show how these obstacles are exacerbated by scientific and regulatory issues in the field.

Various financial obstacles exist for economic development and progress.

1. Growing economic disparity: More inequality impedes everyone's ability to develop

2. Not having access to the necessary infrastructure and technology (highways, trains, internet, etc.)

3.Low human capital - limited access to education and healthcare Less production and knowledge come from healthier or less educated populations.

4. Reliance on the production of the primary sector (fishing, mining, farming, etc.): The economy is severely harmed by one poor yield in a given year.

5. Inability to access global markets: Reduced commerce leads to decreased efficiency.



Fig No 1 :- Economic Barriers

High cost of R and D , financial challenges for pharmaceutical companies

Although the efforts supporting antibiotic research and development are praiseworthy, there are significant weaknesses in the back end of R&D incentives. Making sure that a structured continuum of incentives is provided

that tackles all of the antibiotic's hurdles will help to further strengthen the pipeline value chain. To achieve this continuum, the most beneficial first steps would be to: (1) increase funding for antibiotic clinical trials to help drug candidates submit for regulatory approval; and (2) establish a Market Entry Reward (MER) or Options Market for Antibiotics (OMA) to promote the distribution and commercialization of novel antibiotics. [34]

Push incentivization, or additional direct project funding and support, is particularly necessary during the clinical phases of antibiotic development when expenses are greatest. However, basic science receives about 85% of national-level public funding for antibiotic research and development in Europe . Numerous global funding initiatives, such as CARB-X and JPIAMR, also exclusively allocate funds for the initial phases of antibiotic research and development. Programs like BARDA and the ND4BB COMBACTE initiatives, which specifically fund and assist clinical development, should be expanded to alleviate this. To make sure that viable antibiotics advance to the stage of market approval, it might also be advantageous to combine diverse early-stage R&D funds and repurpose them for later stages.

Furthermore, there is still no consistent, long-term financial incentive for businesses to develop, market, and adequately and fairly distribute a novel antibiotic. This is referred to as incentives for pulling. Many experts have suggested implementing a global MER program as a solution to this problem. A MER is a financial award given to the creator of a novel antibiotic that has been successfully licensed, satisfies predetermined product requirements, and complies with post-market authorization requirements pertaining to patient access and sustainability.[35]

48. The Role Global Collaboration

A WHO report on the creation of national action plans to address the threat of antibiotic resistance, the dire repercussions of inactivity, and the necessity of antibiotic stewardship was published in February 2016. Infection prevention and antibiotic stewardship together constitute a cooperative, interdisciplinary strategy to maximize antibiotic use. Without global learning and coordination, efforts to reduce overuse will not be sustainable. The USA, South Africa, Colombia, Australia, and the UK are the five nations that have evolved distinct approaches to antibiotic stewardship. In this Personal View, we highlight examples of international collaborations to address optimal prescribing. Even though every nation has a different strategy, when supported, individual efforts can have a good impact on national and local antimicrobial stewardship initiatives.

Social media in stewardship, online training programs, national guidelines, cooperative research, government advocacy, and mentoring programs have had an impact. Individual connections and a readiness to share knowledge about each other's achievements and shortcomings continue to encourage cooperation. To address the demands of the world's population, we advise that antibiotic stewardship models move away from infection specialist-based teams and toward the development and utilization of cadres of medical professionals, such as nurses, pharmacists, and community health workers. Additionally, we advise all medical professionals who prescribe antibiotics to take responsibility for their actions, comprehend the social costs associated with inadequate antibiotic usage, and give examples of how nations may collaborate, learn from, and exchange best practices for antibiotic stewardship. Someone who actively builds and maintains ties around the globe is referred to as a global collaborator. This person recognizes the value of diversity in viewpoints, backgrounds, and specializations. They collaborate on projects that cross national boundaries and continents by exchanging ideas and communicating via internet means. For them, working globally is not merely a tactic but also a way of thinking, based on the conviction that coordinated efforts can yield creative answers. The success of international cooperation depends on a few essential competencies. Above all, communication is most noticeable. It is crucial to be able to politely and properly communicate with individuals from various backgrounds.[36]

49. Collaborative Initiatives

In eight nations, GARP facilitated the start of a dialogue for coordinated antibiotic policy, which resulted in the creation of an extensive global antibiotics report that addresses trends in ABR and usage, regulation changes, and the status of the new medication R&D pipeline. It should come as no surprise that resistance rates vary by nation and reflect both antibiotic use and illness trends, according to their 2015 study, The State of World's Antibiotics. The good news is that methicillin-resistant Staphylococcus

aureus (MRSA) infections have decreased in the US, Europe, Canada, and South Africa in recent years. In contrast, sub-Saharan Africa, Australia, Latin America, and India have reported higher rates of MRSA infections (90%) and 47%, respectively. In both inpatient and outpatient settings, unnecessary antibiotic usage (AU) is a serious issue in healthcare. Patients with bacterial infections may benefit from antibiotic treatments, which can save their lives, but there are a number of potentially harmful side effects. Prolonged use of antibiotics has been linked to an increased risk of necrotizing enterocolitis, broncho pulmonary dysplasia, retinopathy of prematurity, fungal infection, and mortality in extremely low birth weight preterm neonates.[4]

An detailed worldwide overview of abr is provided by the who report antimicrobial resistance, global report on surveillance, which includes surveillance and resistance data for bacteria that are categorized as "internationally concerning bacteria." abr's economic and health costs, surveillance difficulties, and suggested future paths for prevention and control are all covered in detail. It should come as no surprise that the primary conclusions of this analysis are heavily impacted by the data accessibility and diverse surveillance techniques employed in different geographical areas. The greatest and worst sources of abr data are the east mediterranean region (32%) and the european region (74%), with other regions falling somewhere in between. The americas account for 60% of the data inputs, followed by the west pacific at 70%, south-east asia at 55%, and africa at 49%. Epidemiological study authors have linked early antibiotic exposure in term infants to higher chances of allergy and topical diseases, as well as higher weight gain in early childhood. The growing neonatal gut microbiome may be impacted by early antibiotic exposures, which could have detrimental implications. Early-life antibiotic exposure is linked to aberrant host development in preclinical animal models, and it can result in long-lasting alterations in the developing microbiota.[37]

50. International efforts to tackle antibiotics resistance

1. Prospective cohort data :- were gathered for ELBW new born (birth weights ranging from 401 to 1000 g) born between They were treated at one of the Neonatal Research Network locations of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) between September 1, 1998, and December 31, 2001. Infants weighing between 401 and 1500 g at birth who are admitted to nicus at participating centers within 14 days of their birth are listed in the network's registry. Using the previousl mentioned general definitions, trained research staff gather data on the mother's sociodemographics, pregnancy, and delivery shortly after birth, as well as the infant's data from birth until 120 postnatal days, discharge, or death. Participation in the register was authorized by each center's institutional review board.[38]

2. Examination :-
To determine the variables linked to the length of the first empirical antibiotic course, the median length of time, and Both for all infants and for infants at specific sites, the prevalence of extended first empirical antibiotic treatment was investigated. Infants who received prolonged initial empirical antibiotic treatment and those who did not were compared based on baseline maternal and neonatal parameters obtained during the first three postnatal days. Wilcoxon tests for continuous variables and two tests for categorical variables were used to assess statistical significance for comparisons. Some continuous variables were not normally distributed, hence nonparametric tests were employed to assess significance for comparisons involving continuous variables.[32]

3. Group Study :- From September 1, 1998, to the present, 5693 babies weighing between 401 and 1000 g were born enrolled in the database and treated at 19 neonatal network clinics as of December 31, 2001. 114 infants who did not receive any initial empirical antibiotic treatment in the first three postnatal days, 125 infants with major birth defects, 80 infants with EOS, 174 outborn infants who were admitted within 24 hours of birth, and 1161 infants who died within five days of birth were among the 1654 infants that were not included in the analysis. 4039 babies who did not have EOS, survived for about five days, had no significant birth abnormalities, and were empirically treated with antibiotics during the first three postnatal days were thus included.
4. Finding the Risk Factors for Extended First Empirical Antibiotic Therapy :- Infants who were empirically treated with antibiotics for approximately five days without a positive culture .The following outcomes were more likely to occur: lower birth weight, lower Apgar scores, blackness, shorter gestational age, and birth approximately 24 hours after membrane rupture. The likelihood that their moms had intrapartum antibiotic therapy was higher.
5. An examination of the relationship with NEC or death and the length :- of the first empirical antibiotic treatment and prolonged initial empirical antibiotic treatment 237 (54% of children with NEC) had Bell stage 3b

NEC (surgical NEC), 203 (46% of infants with NEC) had Bell stage 2a, 2b, or 3a NEC (medical NEC), and 440 (11%) of the 4039 study infants had NEC. Furthermore, 919 (23%) of the 4039 research children experienced the composite outcome of NEC or death, and 658 (16% of 4039) of the infants died after postnatal day 5.

1. One of the biggest dangers to global development and public health is antimicrobial resistance (AMR). Bacterial AMR is thought to have contributed to 4.95 million fatalities worldwide in 2019 and been directly responsible for 1.27 million deaths.

2. Drug-resistant infections are mostly caused by the overuse and abuse of antibiotics in people, animals, and plants.

3. Countries of all income levels and geographical locations are impacted by AMR. Poverty and inequality worsen its causes and effects, with low- and middle-income nations being most impacted.

4. AMR jeopardizes many of the advancements of contemporary medicine. It increases the danger of other medical operations and treatments, including surgery, cesarean sections, and cancer chemotherapy, and makes infections more difficult to treat.

5. There is a global antibiotic access and pipeline crisis. Given the escalating levels of resistance and the pressing need for more steps to guarantee fair access to both new and existing vaccinations, diagnostics, and medications, the pipeline for research and development is insufficient.

6. AMR not only causes death and disability, but it also has high financial expenses. According to World Bank projections, AMR may lead to US$ 1 trillion in increased healthcare expenses by 2050 and US$ 1 trillion to US$ 3.4 trillion in annual GDP losses by 2030. [39]

References:

1. Aminov RI. The role of antibiotics and antibiotic resistance in nature. *Environ Microbiol*. 2009;11(12):2970-2988. doi:10.1111/j.1462-2920.2009.01972.x

2. Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). *Cochrane Database Syst Rev*. 2018;2018(10). doi:10.1002/14651858.CD009764.pub3

3. Harbottle H, Thakur S, Zhao S, White DG. Genetics of antimicrobial resistance. *Anim Biotechnol*. 2006;17(2):111-124. doi:10.1080/10495390600957092

4. Mishra RPN, Oviedo-orta E, Prachi P, Rappuoli R, Bagnoli F. Vaccines and antibiotic resistance. *Curr Opin Microbiol*. 2012;15(5):596-602. doi:10.1016/j.mib.2012.08.002

5. Poole K, Poole K. Annals of Medicine Efflux pumps as antimicrobial resistance mechanisms. 2009;3890. doi:10.1080/07853890701195262

6. Wright GD. Bacterial resistance to antibiotics : Enzymatic degradation and modification. 2005;57:1451-1470. doi:10.1016/j.addr.2005.04.002

7. Gupta PD, Birdi TJ. Journal of Ayurveda and Integrative Medicine Development of botanicals to combat antibiotic resistance. *J Ayurveda Integr Med*. Published online 2017. doi:10.1016/j.jaim.2017.05.004

8. Claeys KC, Fiorvento AD, Rybak MJ. A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii. Published online 2014:69-81. doi:10.1007/s40121-014-0051-9

9. Foti C, Piperno A, Scala A. Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects.

Published online 2021.

10. Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C. Antibiotics for cancer treatment : A double-edged sword. 2020;11. doi:10.7150/jca.47470

11. Coates ARM, Hu Y, Holt J, Yey P. Expert Review of Anti-infective Therapy Antibiotic combination therapy against resistant bacterial infections : synergy , rejuvenation and resistance reduction. *Expert Rev Anti Infect Ther*. 2020;0(0):1. doi:10.1080/14787210.2020.1705155

12. Tortora G, Bianco R, Daniele G, et al. Overcoming resistance to molecularly targeted anticancer therapies : Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 2007;10:81-100. doi:10.1016/j.drup.2007.03.003

13. Grooters KE, Ku JC, Richter DM, et al. Strategies for combating antibiotic resistance in bacterial bio fi lms. 2024;(January):1-7. doi:10.3389/fcimb.2024.1352273

14. Rath D, Amlinger L, Hoekzema M, Devulapally PR. Efficient programmable gene silencing by Cascade. 2015;43(1):237-246. doi:10.1093/nar/gku1257

15. Marks T, Sharp R. Review Bacteriophages and biotechnology : a review. 2000;17(July 1999).

16. Moravej H, Moravej Z, Yazdanparast M, et al. Antimicrobial Peptides : 2018;00(00):1-21. doi:10.1089/mdr.2017.0392

17. Sharma A, Arya DK, Dua M, Chhatwal GS, Johri AK. Nano-technology for targeted drug delivery to combat antibiotic resistance. Published online 2012:1-8.

18. Murugaiyan J, Kumar PA, Rao GS, et al. Progress in Alternative Strategies to Combat Antimicrobial Resistance : Focus on Antibiotics. Published online 2022:1-37.

19. Sehrawat N, Yadav M, Singh M, Kumar V, Sharma VR, Sharma AK. *L P Re*. Elsevier Ltd; 2020. doi:10.1016/j.semcancer.2020.06.009

20. Caballero-flores G, Pickard JM, Núñez G. regulation. 2023;21(6):347-360. doi:10.1038/s41579-022-00833-7.Microbiota-mediated

21. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications : Proposed mechanisms of action. 2008;117:393-405. doi:10.1016/j.pharmthera.2007.11.001

22. Mcconnell MJ. Where are we with monoclonal antibodies for multidrug-resistant infections ? *Drug Discov Today*. 2019;24(5):1132-1138. doi:10.1016/j.drudis.2019.03.002

23. Velkov T, Thompson PE, Nation RL, Li J. Structure - Activity Relationships of Polymyxin Antibiotics. Published online 2010:1898-1916. doi:10.1021/jm900999h

24. Andrei S, Droc G, Stefan G. Focused REVIEW FDA approved antibacterial drugs : 2018-2019. 2019;7(4):2018-2019. doi:10.15190/d.2019.15

25. Dorle MD, Bhivasane A, Sanap GS. REVIEW : CUTANEOUS MUCORMYCOSIS. 2023;12(7):57-69. doi:10.20959/wjpr20237-27831

26. French GL. Clinical impact and relevance of antibiotic resistance. 2005;57:1514-1527. doi:10.1016/j.addr.2005.04.005

27. Tse MW, Weller J, Chen J. Review The future of antibiotics begins with discovering new combinations. 2021;1496:82-96. doi:10.1111/nyas.14649

28. Hutchings M, Truman A, Wilkinson B. ScienceDirect Antibiotics : past , present and future. *Curr Opin*

Microbiol. 2019;51(Figure 1):72-80. doi:10.1016/j.mib.2019.10.008

29. Spellberg B, Gilbert DN. The Future of Antibiotics and Resistance : A Tribute to a Career of Leadership by John Bartlett. 2014;59(Suppl 2):71-75. doi:10.1093/cid/ciu392

30. Alanis AJ. Resistance to Antibiotics : Are We in the Post-Antibiotic Era ? 2005;36:697-705. doi:10.1016/j.arcmed.2005.06.009

31. Manuscript A. MedChemComm. Published online 2017. doi:10.1039/C7MD00528H

32. Riedl R, Chellat MF, Raguz L. Targeting Antibiotic Resistance Angewandte. Published online 2016:6600-6626. doi:10.1002/anie.201506818

33. Monitoring AR. Discovery research : the scientific challenge of finding new antibiotics. 2011;(June):1941-1944. doi:10.1093/jac/dkr262

34. Sanskruti Pawar, Shubhangi Manikpuriya, Gajanan Sanap. The Phytochemical and Pharmacological Screening of Withania Coagulans. *World J Biol Pharm Heal Sci*. 2023;16(3):109-117. doi:10.30574/wjbphs.2023.16.3.0501

35. Renwick M, Mossialos E, Renwick M, Mossialos E. Expert Opinion on Drug Discovery What are the economic barriers of antibiotic R & D and how can we overcome them ? What are the economic barriers of antibiotic R & D and how can we overcome them ? *Expert Opin Drug Discov*. 2018;13(10):889-892. doi:10.1080/17460441.2018.1515908

36. Goff DA, Kullar R, Goldstein EJC, et al. A global call from fi ve countries to collaborate in antibiotic stewardship : united we succeed , divided we might fail. Published online 2017:56-63. doi:10.1016/S1473-3099(16)30386-3

37. Chaudhary AS. PERSPECTIVE A review of global initiatives to fi ght antibiotic resistance and recent antibiotics ' discovery. *Acta Pharm Sin B*. Published online 2016:1-5. doi:10.1016/j.apsb.2016.06.004

38. Bodkhe MAB, Mokle MBA, Sanap G. Lumpy skin disease: An Overview. *Int J Creat Res Thoughts*. 2023;11(3):174-183. https://www.researchgate.net/publication/369139678

39. Cotten CM, Taylor S, Stoll B, et al. Prolonged Duration of Initial Empirical Antibiotic Treatment Is Associated With Increased Rates of Necrotizing Enterocolitis and Death for Extremely. Published online 2014. doi:10.1542/peds.2007-3423